Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsPlatelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysisPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic eventsThe relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Assessment of oral antithrombotic therapy by platelet function testing.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention.Platelet function testing and tailored antiplatelet therapy.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Pharmacogenomics of anti-platelet and anti-coagulation therapy.Personalized antiplatelet therapy: state of the art.Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.Clopidogrel Response Variability: Review of the Literature and Practical Considerations.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity.Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.Thromboembolism after WATCHMAN(TM) in a clopidogrel non-responder: A case for concern?A paradigm shift in anti-platelet therapy?Platelet function profile post-clopidogrel therapy in patients with type 2 diabetes undergoing coronary stent implantation.Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting
P2860
Q26775125-D7A6CA97-F7ED-4899-A183-71449253C9C7Q27010236-390887DE-5212-4F2D-9FFE-BF84D8082417Q27022443-8B39EB95-F96E-4ADC-AE3C-9E562E16E729Q34111144-E2F76826-1262-48A2-9E2F-D9B7EFE83610Q34703779-48A2E3B0-B827-4B20-89E1-CD3965815FE9Q37497555-30EE3641-731C-4777-9BE5-504B5775C097Q37540088-6180262B-17A9-463A-AF60-62EBBA2BCF6EQ37765291-2F0A5298-D53A-4D37-A6AA-AD92B1B2AE68Q37882712-F61DB297-331F-436B-B335-2DF10C410F85Q37902507-9A4F1356-99A5-4199-B57D-CF0AAC04B32BQ37923969-F2A17CE5-4C7F-491A-9137-02F725D5F062Q38012079-FB895982-2EC0-4CFC-A733-5BDD83286D4AQ38048837-71D1288C-997D-47B9-8E3A-0BCD22BD9664Q38056525-8C06F7F2-EC26-44B0-BA84-A68B062BD3A1Q38094681-81A7F906-8D0E-4DEA-B4CE-93BD521B91DEQ38099235-A7E83BB9-B8AA-4F81-86A9-C2DD8F27004CQ38116753-18C40353-96C7-464D-95C6-13F01497A88FQ38156786-00ACD61C-6D87-4071-AF68-86337486F0D0Q38375641-6D76126D-CE51-4FCD-9AD0-6B1FCC125FDEQ38640902-39248D92-3778-456A-9CE5-AFEB88359F58Q38958862-92A8CAEF-8037-4AB4-B3EC-63309956D5B8Q39704629-27EDF2FB-0572-472F-B4CC-8401D126DF3FQ44426942-19EAA867-8F24-45D5-8DEF-3E81879A2F25Q45072764-AB013CFF-9106-4ADB-BF02-D03FDC27B32BQ46244126-928063E2-AF37-4E8C-BCB6-EA7F2C083B1AQ46358660-08932D67-3598-46AE-A915-254E17F59D78Q58841190-0D713D24-75D2-4E8F-9D61-F957A457527D
P2860
Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@en
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@nl
type
label
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@en
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@nl
prefLabel
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@en
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@nl
P2093
P2860
P1433
P1476
Platelet reactivity to adenosi ...... tiplatelet therapeutic target.
@en
P2093
Anand Singla
Joseph Dichiara
Kevin P Bliden
Mark J Antonino
Paul A Gurbel
Thomas A Suarez
Udaya S Tantry
P2860
P304
P356
10.1080/09537100802351065
P577
2008-12-01T00:00:00Z